Researchers at the University of California San Diego have uncovered the structural mechanisms that cause congenital myasthenic syndromes (CMS), revealing mutation-specific treatment strategies and identifying an existing antidepressant as a promising candidate for drug repurposing.
The study, published in Nature, explains how disease-causing mutations alter the human acetylcholine receptor (AChR), the protein responsible for converting nerve signals into muscle contraction. The findings also provide a framework for developing precision medicines tailored to the specific mutation carried by individual patients.
CMS is a rare inherited group of neuromuscular disorders that typically appears at birth or early childhood. Mutations in the AChR impair communication between nerves and muscles, leading to muscle weakness, difficulty walking, breathing problems, and, in severe cases, paralysis or death. Although more than 50 disease-causing mutations have been identified, the molecular mechanisms underlying these disorders have remained largely unknown.
To address this question, the investigators determined 12 high-resolution structures of representative mutant AChRs with and without therapeutic compounds. By combining these structural data with functional studies, they identified common mechanisms that explain the two major forms of CMS.
Fast-channel CMS is caused by loss-of-function mutations that reduce receptor opening and weaken neuromuscular transmission. The researchers discovered a previously unknown allosteric binding pocket that can be targeted by positive allosteric modulators (PAMs), compounds that enhance receptor activity without directly activating the channel.
Notably, different PAMs restored receptor function in different patient mutations rather than producing a universal effect. The authors write that this “mutation-specific activity underscores the capability and necessity of tailoring therapies to individual patient genotypes.”
The study also showed that the newly identified drug-binding pocket is largely absent until a PAM binds, creating an opportunity to design more effective compounds that stabilize receptor function. The authors conclude that these findings point to “a new class of allosteric drugs” with potential applications not only in fast-channel CMS but also in disorders such as myasthenia gravis, in which acetylcholine receptor function is compromised.
The team also investigated slow-channel CMS, a gain-of-function disorder in which receptors remain open too long, causing excessive calcium influx and progressive damage at the neuromuscular junction.
Structural analyses revealed that the current therapies quinidine and fluoxetine act through a shared mechanism, blocking the receptor pore despite their distinct chemical structures.
The investigators also evaluated reboxetine, an antidepressant already approved in several countries. Unlike the existing drugs, reboxetine selectively inhibited abnormal receptor activity across multiple slow-channel mutations while largely sparing normal receptor function.
The authors believe that reboxetine’s ability to suppress pathological receptor activity, together with its established clinical safety profile, “positions it as a potential candidate for slow-channel CMS therapy,” although they caution that its known adverse effects warrant careful evaluation in future clinical studies.
Beyond identifying therapeutic opportunities, the study establishes unifying principles of CMS pathogenesis. The researchers found that fast-channel mutations weaken the coupling between acetylcholine binding and channel opening, whereas slow-channel mutations stabilize an abnormally widened, desensitized-like pore. These shared structural mechanisms explain why genetically diverse mutations produce similar clinical symptoms while requiring different therapeutic strategies.
The work also revises understanding of receptor biology. The authors write that their findings “overturn the traditional view of the β subunit as merely a structural scaffold,” instead demonstrating that it plays “a central role in the gating cycle.”
Overall, the researchers conclude that their integrated structural and functional analyses define how CMS mutations disrupt receptor gating, reveal the molecular basis of current and candidate therapies, and identify new druggable sites for intervention. They conclude that the work provides “a roadmap towards the development of safer and more effective, mutation-specific treatments for both fast-channel and slow-channel CMS.”
The post Structural Biology Reveals New Drug Targets for Rare Neuromuscular Disease appeared first on Inside Precision Medicine.